Becton, Dickinson & Stock News

FRANKLIN LAKES, N.J. , Oct. 30, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today launched the new BD® Intraosseous Vascular Access System, enabling access for rapid delivery of fluids or medication in critical emergency situations.

The ProShares S&P 500 Dividend Aristocrats ETF went on a great run during Q3, gaining 11.6% during the quarter. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 39 months of tracking these strategies, all 3 strategies are generating a CAGR superior to NOBL while also offering a higher dividend yield.

FRANKLIN LAKES, N.J. , Oct. 25, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has been named as one of the 100 Best Corporate Citizens of 2024 by 3BL, ranking second in the health care equipment and services industry for its second consecutive year.

Automation-Ready Reagents Used with the Hamilton Robotics Liquid-Handler Streamlines and Helps Accelerate Lab Work Leading to Genomic Sequencing  FRANKLIN LAKES, N.J. , Oct. 14, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the commercial launch of the first in a family of high-throughput, robotics-compatible re...

Announces Dates for Fiscal 2025 Quarterly Earnings Webcasts FRANKLIN LAKES, N.J. , Oct. 10, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will report financial results for its fiscal 2024 fourth quarter and full year on Thursday, Nov. 7, 2024.

Dividend Kings have a 50+ year track record of increasing dividends, showcasing resilience through economic challenges. I rank Dividend Kings by quality score and highlight undervalued stocks for potential investment. The article provides tables and charts presenting quality scores, key metrics, and fair value estimates.

No admission of liability or wrongdoing; settlement structured to eliminate uncertainty for all stakeholders related to settled cases. Settlement amount within current product litigation reserve and will be paid out over a multi-year period.

The ProShares S&P 500 Dividend Aristocrats ETF extends it's good form in the second half of 2024, adding a gain of 3.69% in August. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 38 months of tracking these strategies, all 3 strategies are generating a CAGR superior to NOBL while also offering a higher starting dividend yield.